Centessa Pharmaceuticals pulls off massive $225m deal—Stock price jumps
Centessa Pharmaceuticals has experienced a substantial rise in its share price after completing an upsized public offering of American Depositary Shares (ADSs). The company, listed ... Read More
Suven Life Sciences announces positive results from Samelisant Phase-2 study
Suven Life Sciences, a pioneering biopharmaceutical company specializing in Central Nervous System (CNS) disorders, recently announced the successful completion of its Phase-2 proof-of-concept study for ... Read More
Takeda halts TAK-994 narcolepsy treatment development due to hepatotoxicity concerns
Takeda's pioneering Phase 2 trial of TAK-994, a potential treatment for narcolepsy type 1 (NT1), came to an abrupt halt due to hepatotoxicity concerns, according ... Read More
Suven Life Sciences set to begin samelisant phase 2 trial in narcolepsy
Suven Life Sciences has announced the successful completion of enrollment for its phase-2 proof-of-concept (PoC) clinical study to evaluate the safety and efficacy of samelisant ... Read More